Thymalfasin for the treatment of chronic hepatitis C infection.

Article Details

Citation
Copy to clipboard

Rustgi VK

Thymalfasin for the treatment of chronic hepatitis C infection.

Expert Rev Anti Infect Ther. 2005 Dec;3(6):885-92.

PubMed ID
16307501 [ View in PubMed
]
Abstract

Approximately 50% of treatment-naive hepatitis C patients fail to achieve a sustained virologic response with standard peginterferon and ribavirin therapy. Patients who are infected with genotype 1 have high viral loads and are nonresponders to previous therapy, and are even more difficult to treat, underscoring the need for new therapeutic options. Thymalfasin (thymosin-alpha1), in combination with peginterferon-alpha2a, has demonstrated efficacy among difficult-to-treat patients with hepatitis C. The addition of ribavirin to thymalfasin and peginterferon-alpha2a has also exhibited promising results among patients who have genotype 1 hepatitis C, high viral loads and are nonresponders to previous therapy.

DrugBank Data that Cites this Article

Drugs